Hypercalcemia in patients treated with CAPD.

Area of Science:

• Nephrology
• Internal Medicine
• Biochemistry

Background:

• Continuous ambulatory peritoneal dialysis (CAPD) is a common renal replacement therapy.
• Hypercalcemia is a potential complication in CAPD patients, influenced by dialysate calcium concentration.
• Accurate detection of hypercalcemia is essential for patient management.

Purpose of the Study:

• To investigate the incidence of hypercalcemia in CAPD patients using dialysate solutions with calcium concentrations of 1.75 mmol/l and 1.25 mmol/l.
• To compare the diagnostic accuracy of total calcium versus ionized calcium measurements in detecting hypercalcemia during CAPD.
• To assess the safety and efficacy of different dialysate calcium levels in preventing hypercalcemia.

Main Methods:

• A prospective study involving 11 CAPD patients over 48 weeks.
• Patients were treated sequentially with dialysate solutions containing Ca 1.75 mmol/l for 24 weeks, followed by Ca 1.25 mmol/l for 24 weeks.
• Serum calcium levels (total and ionized) were measured at baseline, and at weeks 2, 12, and 24 of each treatment phase.

Main Results:

• Total calcium measurements identified only three episodes of hypercalcemia.
• Ionized calcium measurements revealed a significantly higher incidence, with 12 episodes diagnosed across all measurement points during the Ca 1.75 mmol/l phase.
• No hypercalcemia episodes were observed during treatment with the Ca 1.25 mmol/l dialysate solution.

Conclusions:

• Ionized calcium measurement is superior to total calcium for detecting hypercalcemia in CAPD patients.
• Using a lower dialysate calcium concentration (1.25 mmol/l) effectively prevents hypercalcemia in CAPD patients.
• Optimizing dialysate composition is critical for managing electrolyte balance and preventing complications in CAPD therapy.